COVID-19 vaccine

Yicai: WHO Says Rich Countries Should Fulfill Their Promise of Providing Vaccines Fairly

Retrieved on: 
Monday, March 1, 2021
Infectious diseases, General Health, Pharmaceutical, Health, World Health Organization, COVID-19, Tedros Adhanom, Ghebreyesus, Medical specialties, COVAX, Vaccine, Health, Medical research, World Health Organization's response to the COVID-19 pandemic, COVID-19 vaccine

Secretary-General Tedros Adhanom Ghebreyesus accused rich countries of competing for various vaccines in large quantities, but few vaccines were delivered to underdeveloped countries.

Key Points: 
  • Secretary-General Tedros Adhanom Ghebreyesus accused rich countries of competing for various vaccines in large quantities, but few vaccines were delivered to underdeveloped countries.
  • Tedros said that some rich countries deal directly with manufacturers, and the number of vaccines distributed to third world countries through COVAX agreement is decreasing.
  • Only when rich countries respect COVAX's agreement can COVAX member countries get vaccines."
  • Governments, vaccine manufacturers and the international community need to take urgent actions to fulfill the promise of providing vaccines fairly.

India $2.3 Billion COVID-19 Vaccines Market to 2027: Approval/Launches of New Vaccines / Rising Focus on Immunization Programs / Increasing Government Support for Vaccine Development

Retrieved on: 
Monday, March 1, 2021
Vaccination, Vaccine, Virology, Medical specialties, COVID-19 vaccine, Medicine, Health sciences, World Health Organization, COVID-19

India's COVID-19 vaccines market is anticipated to grow over US$ 2.3 Billion by 2027 with an impressive CAGR of more than 25% during the forecast period.

Key Points: 
  • India's COVID-19 vaccines market is anticipated to grow over US$ 2.3 Billion by 2027 with an impressive CAGR of more than 25% during the forecast period.
  • The report offers the most up-to-date industry data on the actual market situation and future outlook for the India COVID-19 vaccines market.
  • The report also delivers a detailed assessment of the latest happenings in the Indian COVID-19 vaccines market.
  • The report concludes with the profiles of the key players in the Indian COVID-19 vaccines market.

Statement from the Chief Public Health Officer of Canada on March 1, 2021

Retrieved on: 
Monday, March 1, 2021
Medical research, Medicine, Health sciences, COVID-19 vaccine, Medical specialties, Vaccine, Vaccines, World Health Organization, COVID-19 vaccination in Bulgaria, Deployment of COVID-19 vaccines

COVID-19 vaccines continue to roll-out in priority vaccination programs across Canada and last week Health Canada authorized two more safe and effective COVID-19 vaccines for use in Canada .

Key Points: 
  • COVID-19 vaccines continue to roll-out in priority vaccination programs across Canada and last week Health Canada authorized two more safe and effective COVID-19 vaccines for use in Canada .
  • The authorization of additional vaccines provides further tools to fight this pandemic as quickly as possible, and will provide more supply to the market.
  • Any easing of public health measures must be done slowly with enhanced testing, screening, and genomic analysis to detect variants of concern.
  • These factors underscore the importance of enhanced public health measures where needed and maintaining strict adherence to individual precautions.

Publix Pharmacies to Offer Doses of the COVID‑19 Vaccine at 58 South Carolina Stores

Retrieved on: 
Monday, March 1, 2021
Retail, Health, Consumer, Infectious diseases, Seniors, Supermarket, Pharmaceutical, Publix, Medical research, COVID-19 vaccine, Economy of the United States, Southeastern United States, Companies

Publixs online reservation system will open tomorrow morning for COVID-19 vaccination appointments at 58 Publix pharmacies in South Carolina.

Key Points: 
  • Publixs online reservation system will open tomorrow morning for COVID-19 vaccination appointments at 58 Publix pharmacies in South Carolina.
  • View a full list of South Carolina pharmacies offering appointments for the COVID-19 vaccine.
  • Publix pharmacies have also administered the COVID19 vaccine to eligible individuals in select Florida, Georgia and Virginia locations.
  • Publix, the largest employee-owned company in the U.S. with more than 225,000 associates, currently operates 1,266 stores in Florida, Georgia, Alabama, Tennessee, South Carolina, North Carolina and Virginia.

FedEx Prepares For COVID-19 Vaccine Volume Growth, Begins Shipping Newly Approved Vaccine

Retrieved on: 
Monday, March 1, 2021
Trucking, Health, Air, Infectious diseases, Logistics, Supply chain management, Transport, Pharmaceutical, FedEx, Express mail, Transport, Airlines, Medical research, FDX, COVID-19 vaccine, Aviation

FedEx Express, a subsidiary of FedEx Corp. (NYSE: FDX) and the worlds largest express transportation company, announced today that it has begun shipping the newly approved COVID-19 vaccine on behalf of McKesson Corp. to dosing centers throughout the United States.

Key Points: 
  • FedEx Express, a subsidiary of FedEx Corp. (NYSE: FDX) and the worlds largest express transportation company, announced today that it has begun shipping the newly approved COVID-19 vaccine on behalf of McKesson Corp. to dosing centers throughout the United States.
  • As vaccine production ramps up and more vaccines are approved, we expect to see a significant uptick in COVID-19 vaccine and supply kit volume moving through our network, said Don Colleran, president and CEO for FedEx Express.
  • FedEx SenseAware ID, a Bluetooth low-energy sensor device, is affixed to vaccine shipments, helping to ensure these temperature-sensitive deliveries move swiftly and safely through the FedEx Express U.S. network with FedEx Priority Overnight service.
  • To learn more about how FedEx connects people and possibilities around the world, please visit about.fedex.com .

Nomi Health Opens More Vaccine Appointments at More Locations for Eligible Utahns Ages 16+ via getmyshot.utah.gov

Retrieved on: 
Monday, March 1, 2021
Infectious diseases, Pharmaceutical, Health, COVID-19 vaccines, Clinical trials, Health sciences, Medicine, Health, Medical research, Pfizer, Pfizer–BioNTech COVID-19 vaccine, COVID-19 vaccine, Vaccine

All eligible residents, ages 16+, can now register and receive an appointment for the Pfizer COVID-19 vaccine at one of four Larry H. Miller Megaplex locations via https://getmyshot.utah.gov/ .

Key Points: 
  • All eligible residents, ages 16+, can now register and receive an appointment for the Pfizer COVID-19 vaccine at one of four Larry H. Miller Megaplex locations via https://getmyshot.utah.gov/ .
  • As the State expands its eligibility for vaccines, Nomi Health is partnering with the Department of Health to ensure as many Utahns as possible can get their shots, explained Dr. June Steely, Medical Director, Nomi Health.
  • For any questions, call the vaccine program helpline at (801) 704-5911, where support is also available in both English and Spanish.
  • Our COVID-19 public health testing and vaccine programs are a perfect example of a more direct, digital-first health care model at work.

Castlight Health Launches New Resource to Help Employers Address COVID-19 Vaccine Navigation and Vaccine Literacy

Retrieved on: 
Monday, March 1, 2021
Castlight Health, COVID-19 vaccine, Vaccine, Medicine, Medical specialties, Health sciences

SAN FRANCISCO, March 1, 2021 /PRNewswire/ -- Castlight Health, Inc. (NYSE: CSLT), a leader in healthcare navigation, today announced a new COVID-19 vaccine navigation feature embedded directly into the Castlight app.

Key Points: 
  • SAN FRANCISCO, March 1, 2021 /PRNewswire/ -- Castlight Health, Inc. (NYSE: CSLT), a leader in healthcare navigation, today announced a new COVID-19 vaccine navigation feature embedded directly into the Castlight app.
  • Vaccine Navigation is the latest example of how Castlight is helping its employer customers and their employees navigate the complex healthcare landscape during the pandemic.
  • The Castlight Vaccine Navigation feature launched in February and was provided at no additional cost to the company's customers.
  • Castlight's Vaccine Navigation also addresses vaccine confusion and hesitancy head-on by providing digestible, high-quality educational content that covers topics such as vaccine safety, effectiveness, and potential side effects.

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

Retrieved on: 
Monday, March 1, 2021
Health, Zoonoses, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Pandemics, Coronavirus disease, COVID-19 vaccine, Severe acute respiratory syndrome, Vaccine, Virus

Once the amino acid sequences for the variants are available, BioVaxys should be able to quickly produce a multivalent vaccine.

Key Points: 
  • Once the amino acid sequences for the variants are available, BioVaxys should be able to quickly produce a multivalent vaccine.
  • BioVaxys is also planning a product line extension of Covid-T, its disposable diagnostic for screening for T cell responseto SARS-CoV-2, that would have capability to screen for T-cell responses to SARS-CoV-2 variants.
  • Most disconcerting are findings that recently approved Covid-19 vaccines may not work as well against these variants.
  • Given the nature of viruses and their natural propensity to mutate, it is likely that additional clinically significant variants will emerge.

BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants

Retrieved on: 
Monday, March 1, 2021
Health, Zoonoses, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Pandemics, Coronavirus disease, COVID-19 vaccine, Severe acute respiratory syndrome, Vaccine, Virus

Once the amino acid sequences for the variants are available, BioVaxys should be able to quickly produce a multivalent vaccine.

Key Points: 
  • Once the amino acid sequences for the variants are available, BioVaxys should be able to quickly produce a multivalent vaccine.
  • BioVaxys is also planning a product line extension of Covid-T, its disposable diagnostic for screening for T cell responseto SARS-CoV-2, that would have capability to screen for T-cell responses to SARS-CoV-2 variants.
  • Most disconcerting are findings that recently approved Covid-19 vaccines may not work as well against these variants.
  • Given the nature of viruses and their natural propensity to mutate, it is likely that additional clinically significant variants will emerge.

Flowserve Supports Pfizer in the Production of COVID-19 Vaccine

Retrieved on: 
Monday, March 1, 2021
Manufacturing, Other Manufacturing, Health, Pharmaceutical, Engineering, Medical research, Health sciences, Pfizer, Flowserve, Companies, Life sciences, COVID-19 vaccines, COVID-19 vaccine, Clinical trials

During the engineering runs of vaccine production Pfizer needed immediate support to replace a mechanical mixer seal on its COVID-19 vaccine production line.

Key Points: 
  • During the engineering runs of vaccine production Pfizer needed immediate support to replace a mechanical mixer seal on its COVID-19 vaccine production line.
  • Additionally, Flowserve through its channel partner, Corrosion Fluid Products, is providing Pfizer with a cryogenic valve application to support their expanded production capabilities of the COVID-19 vaccine.
  • The Flowserve Cookeville, Tennessee facility will supply Pfizer with more than 200 Worcester cryogenic ball valves that can handle the rigorous temperature requirements needed in supporting the mass production of the COVID-19 vaccine.
  • And finally, Flowserves Chesapeake, Virginia and Itzehoe, Germany pump manufacturing facilities are providing pumps to Pfizer for both their North American and European vaccine production.